Selvita opens new research site in Poznan
The initial laboratory space will amount to 5,500 sq. ft, which constitutes nearly 20% increase in Selvita laboratory space, compared to the current state with significant extension possibilities.
Selvita has signed a contract for the lease of laboratory space in Poznan, Poland. The new site will be located at in the Wielkopolska Centre of Advanced Technologies and commence research activities in the summer of 2016. The initial laboratory space will amount to 5,500 sq. ft, which constitutes nearly 20% increase in Selvita laboratory space, compared to the current state with significant extension possibilities.
The Poznan facility will be the first Selvita research site outside Krakow and its opening will fulfil one of the strategic goals presented during Selvita’s IPO in December 2014.
At the beginning, Selvita plans to employ approximately 50 people in Poznan — primarily chemists and biologists — gradually increasing their number in subsequent periods. Ultimately, the facility in Poznan is meant to be the "second heart of Selvita", providing both contract services, as well as actively participating in internal R&D projects.
"Wielkopolska region has a fantastic scientific potential. We are fully aware that for many talented graduates from local universities, the decision to relocate to Krakow can be very difficult, and for this reason we decided to come to them" says Dr Miroslawa Zydron, Director of the Contract Chemistry Department and Member of the Management Board at Selvita. "The foundation of Poznan team will be the employees coming from that region, who have already been working at Selvita for some time, in our laboratories in Krakow. Recently we have been also recruiting locally in Poznan. Selected candidates are being invited to join Selvita for a few months in Krakow, so they can have the opportunity to get to know our company and its organization, before they start working in Poznan" she added.
Selvita headquarters and the main laboratories with a research space of 30,000 sq. ft, are located in Krakow, Poland. In 2015, Selvita opened its subsidiaries in major biotech centers in the world — Selvita Inc. in the Greater Boston Area, in the San Francisco Bay Area in US and Selvita Ltd in Cambridge, UK.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance